Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
MedImmune, Inc. is a biotechnology company that uses advances in biological sciences to discover, develop, manufacture and commercialize products that treat or prevent infectious diseases, immune system disorders and cancer. MedImmune's core competencies are in the areas of monoclonal antibodies and vaccines. The Company promotes three main products: Synagis (palivizumab) and FluMist (Influenza Virus Vaccine Live, Intranasal), used to prevent two common respiratory infectious diseases, and Ethyol (amifostine), used to reduce undesired side-effects of certain anti-cancer chemo- and radiotherapies. MedImmune also markets three additional products: CytoGam, NeuTrexin and RespiGam.

Financial Information
For the nine months ended 9/04, revenues rose 4% to $675.3M. Net loss totalled $54.3M vs. an income of $106.6 million. Results reflect higher sales of Synagis and the launch of FluMist, offset by a $73 million impairment charge.